Pre-Immunosuppressant Baseline Investigations for Rheumatoid Arthritis

What You Ordered - Assessment

Complete Baseline Workup

1. Haematological

• CBC with differential - Most important missing test. MTX, leflunomide, sulfasalazine all cause cytopenias (pancytopenia, leukopenia, thrombocytopenia). Baseline required before starting any of these.

2. Renal

• Serum creatinine + eGFR - MTX is renally cleared; renal impairment dramatically increases toxicity risk. Contraindicated in significant CKD. Also needed for leflunomide.
• Urine routine examination (some guidelines) - to detect baseline proteinuria.

3. Hepatic (you have this)

• LFT (AST, ALT, ALP, bilirubin, albumin) - Already ordered. ✅
• Albumin specifically indicates chronic liver disease/nutritional status.

4. Infection Screening (largely covered)

• HBsAg + anti-HBc (total) - You ordered HBsAg, but anti-HBc (core antibody) should also be checked. Patients with occult HBV (HBsAg negative but anti-HBc positive) are still at reactivation risk with biologics.
• HCV antibody - ✅ Already ordered.
• HIV - ✅ Already ordered.
• Mantoux/TST - ✅ Already ordered. Note: in immunosuppressed patients or BCG-vaccinated individuals, IGRA (Interferon Gamma Release Assay / QuantiFERON-TB Gold) is more specific and preferred over Mantoux before biologics.

5. Chest X-Ray

• CXR (PA view) - Screens for active/old TB, pulmonary fibrosis, and provides a baseline for MTX-induced pneumonitis. Often missed but required per ACR/BSR guidelines.

6. Serology / Autoimmune

• RA factor (RF) + anti-CCP - If not already done, confirms diagnosis and guides prognosis.
• ANA - Baseline, especially if considering biologics that can induce drug-related lupus.
• ESR / CRP - Baseline disease activity markers for monitoring treatment response.

7. Lipid Profile

• Fasting lipid profile - Mandatory before JAK inhibitors (tofacitinib, baricitinib), which raise LDL/triglycerides. Also relevant for general cardiovascular risk assessment in RA patients (who have high CV burden).

8. Blood Sugar

• Fasting blood glucose / HbA1c - Especially if corticosteroids co-prescribed; also relevant for JAK inhibitor use.

9. Pregnancy Test

• Urine/serum beta-hCG in women of childbearing potential - MTX and leflunomide are both Category X teratogenic drugs - absolute contraindication in pregnancy.

10. Drug-Specific Additions

Summary Checklist

Key Things to Add to Your Current Order

1. CBC with differential - single most critical missing test
2. Serum creatinine / eGFR
3. Chest X-ray
4. Anti-HBc (hepatitis B core antibody) - supplements your HBsAg
5. Pregnancy test (if applicable)
6. Fasting lipid profile (especially if planning biologics or JAK inhibitors)
7. Consider IGRA instead of or in addition to Mantoux if biologic therapy is planned

Latest EULAR / ACR Guidelines on Pre-DMARD Screening for RA

EULAR 2025 Update (Published March 2026)

EULAR Infection Screening Positions (Current)

Key EULAR expansion (vs. older guidance): EULAR now recommends HBV/HCV screening prior to any immunosuppressive therapy - not just biologics. This includes csDMARDs and even glucocorticoids. LTBI screening is also considered before csDMARDs in high-risk individuals.

ACR Positions (2021 Guidelines + Current Practice)

APLAR 2024 Update (Asia-Pacific)

• Covers vaccination and screening for infections as a formal statement
• Addresses reactivation risk in endemic regions (TB, HBV)
• Emphasises managing RA in patients with pre-existing viral hepatitis

Real-World Audit Data (Pakistan, 2025)

• 20.2% had latent TB - all received prophylaxis, zero reactivations
• 14.7% had occult HBV (anti-HBc positive), 5.1% had active infection
• 9.6% had HCV - none needed treatment (HCV RNA negative)

Guideline Comparison: What's New vs. Old Practice

Practical Take-Home for Your Practice

1. Add anti-HBc alongside HBsAg - EULAR requires both
2. Upgrade Mantoux to IGRA (QuantiFERON-TB Gold) if available - more specific, especially post-BCG
3. Add CXR - both EULAR and ACR require it for TB screening (not just if Mantoux positive)
4. Add CBC and serum creatinine - the most commonly missed haematological/renal baselines
5. Add pregnancy test for women of childbearing potential if MTX planned

• EULAR 2025 RA Update (PMID 41826212) - Ann Rheum Dis 2026
• EULAR Screening Evidence - PMC11993486 - Clin Rheumatol 2025
• APLAR 2024 Recommendations (PMID 42362943) - Int J Rheum Dis 2026
• Clinical Audit Pakistan (PMID 40621538) - Pak J Med Sci 2025

Methotrexate vs Tofacitinib in Rheumatoid Arthritis

1. Drug Class & Mechanism

2. Position in Treatment Guidelines

• MTX is first-line - "MTX should be part of the first treatment strategy" (EULAR 2025, Recommendation 4)
• Tofacitinib is second/third-line - considered after inadequate response to csDMARDs, with careful risk assessment
• Both guidelines add boxed warnings for JAK inhibitors regarding cardiovascular, malignancy, and thromboembolic risk

3. Efficacy Comparison

Head-to-Head Evidence

• Tofacitinib 5 mg BD monotherapy vs Tofacitinib 5 mg + MTX vs Adalimumab + MTX
• Tofacitinib + MTX was non-inferior to adalimumab + MTX in ACR50 response
• Tofacitinib monotherapy was numerically inferior to combination therapy
• Key takeaway: JAK inhibitor + MTX together beats either alone

• 116 DMARD-naive RA patients, moderate-high disease activity
• TOFA 5 mg BD monotherapy vs MTX 10-20 mg/week + betamethasone bridging
• Primary endpoint at 3 months: TOFA group 94.1% vs MTX group 75.0% improvement (p=0.02)
• TOFA showed greater SDAI, CDAI, and DAS28 reductions at 3 months
• Safety comparable; tofacitinib showed superior cost-effectiveness
• Conclusion of trial: "TOFA as a potential first-line bridging option" - this is a notable claim, but the trial was open-label, small (n=116), short-term (3 months), and conducted in China - so it does not yet overturn international guideline consensus

• JAK inhibitor + MTX showed higher ACR50, ACR70, remission rates than JAK inhibitor monotherapy at weeks 24 and 52
• Combination had higher adverse event rates but similar serious adverse events

4. Safety - The Critical Differentiator

Methotrexate Safety Concerns

• Hepatotoxicity - most common; requires LFT monitoring
• Myelosuppression - CBC monitoring mandatory
• Teratogenicity - Category X; must be stopped 3 months before conception
• Pulmonary toxicity (rare) - MTX pneumonitis
• GI side effects - nausea, mucositis; mitigated by folic acid supplementation
• Renal impairment - dose-adjusted or avoided if GFR <30

Tofacitinib Safety Concerns - More Serious

• 4,362 patients ≥50 yrs with ≥1 cardiovascular risk factor, followed for median 4.0 years
• Tofacitinib (both 5 mg and 10 mg BD) vs TNF inhibitor (adalimumab or etanercept)
• MACE (major adverse cardiovascular events): Tofacitinib 3.4% vs TNF-i 2.5% - HR 1.33 (95% CI 0.91-1.94) - non-inferiority NOT met
• Cancers: Tofacitinib 4.2% vs TNF-i 2.9% - HR 1.48 (95% CI 1.04-2.09) - statistically significantly higher
• Higher rates of: opportunistic infections, herpes zoster (including serious), PE/DVT, non-melanoma skin cancer
• This trial led the FDA and EMA to add boxed warnings across all JAK inhibitors

5. Who Gets Which Drug - Decision Framework

6. The Bottom Line

• ORAL Surveillance - NEJM 2022 (PMID 35081280) - CV and cancer risk with tofacitinib
• Zhao et al. - Mayo Clin Proc Jul 2026 (PMID 41932389) - Tofacitinib vs MTX in DMARD-naive RA
• Liu et al. - Front Immunol 2022 (PMID 36248913) - JAKi ± MTX meta-analysis
• EULAR SLR for 2022 update (PMID 36368906) - csDMARD vs bDMARD/tsDMARD efficacy
• EULAR 2025 RA Recommendations (PMID 41826212) - Current guideline

1. Methotrexate - Starting Dose and Escalation

Dosing Schedule

• Target at least 15 mg/week within 4-6 weeks of initiation (conditional recommendation)
• Oral MTX is preferred over SC for initiation
• If oral MTX is not tolerated, split the dose over 24 hours (e.g., half in morning, half at night) or switch to SC before giving up on MTX

• "Start at 15 mg/week, escalate with 5 mg/month to 25-30 mg/week or highest tolerable dose"
• SC MTX if oral at maximum dose shows insufficient response

Why Escalate Quickly?

Oral vs Subcutaneous MTX

• Splitting oral MTX across 2 doses (e.g., morning + evening, 12 hours apart) also improves bioavailability

Folic Acid - Mandatory Co-prescription

• 5 mg once weekly (on a different day from MTX), or 1 mg daily
• Reduces GI side effects, mucositis, and hepatotoxicity without reducing efficacy
• Always prescribed alongside MTX from Day 1

How Long Before Assessing Response?

• Minimum 3 months to determine if improving
• Full assessment at 6 months - if target (remission or LDA) not reached at 6 months, escalate or add therapy

2. Leflunomide - Role and Dosing

Position in RA Treatment

Leflunomide Dosing

Leflunomide Safety Points

• Hepatotoxicity - requires LFT monitoring (same schedule as MTX)
• Teratogenicity - Category X; extremely long half-life means cholestyramine washout protocol needed before pregnancy (cholestyramine 8 g TDS x 11 days until plasma levels undetectable)
• Hypertension - monitor BP
• Avoid combining with MTX unless careful monitoring planned (additive hepatotoxicity)

3. Steroids (Glucocorticoids) - Duration and Role

Role: Bridging Therapy Only

What the Guidelines Say

• Short-term steroids (<3 months): conditionally acceptable as bridging
• Long-term steroids (≥3 months): strongly NOT recommended - this is a strong recommendation in ACR 2021

Typical Steroid Bridging Regimens

• Higher-dose bridging (60 mg → 7.5 mg over 7 weeks) gave significantly better early DAS remission (63% vs 29%) and lower HAQ at 3-4 months
• Counterintuitively, fewer adverse events with the higher-dose group (because disease was better controlled)
• Note: this compares two clinical trials, not a direct head-to-head - interpret cautiously

Duration Rules in Practice

Steroid Adverse Effects to Monitor

• Osteoporosis - calcium + Vitamin D supplementation; bisphosphonate if long-term steroid use
• Blood glucose - especially in diabetics or pre-diabetics
• Blood pressure - hypertension risk
• Infection - increased susceptibility
• Cushingoid features with prolonged use

Summary Table

• ACR 2021 RA Treatment Guidelines (PMC9273041)
• EULAR 2025 Update (PMID 41826212)
• Steroid Bridging RCT - van der Pol 2025 (PMID 40367657)
• MTX Dosing Systematic Review (PMC2689521)
• Leflunomide FDA Prescribing Information